Positron emission tomography in the detection and management of metastatic melanoma

Melanoma Research

Volumn 6, Issue 4, 1996, Pages 325-329

  Damian, D L ^a   Fulham, M J ^a   Thompson, E ^a   Thompson, J F ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Melanoma; Metastatic; Positron emission tomography; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; X RAY ANALYSIS;

EID: 0029809019     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199608000-00008     Document Type: Article

References (21)

1. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
2. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
3. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
4. Crowe JP, Adler LP, Shenk RR, et al. Positron emission tomography and breast masses: comparison with clinical, mammographic and pathological findings. Ann Surg Oncol 1994; 1: 132-140.
5. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumours: PET evaluation. Radiology 1989; 170: 329-332.
6. Bares R, Klever P, Hauplmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86.
7. Weber G. Enzymology of cancer cells. N Engl J Med 1977; 296: 486-493, 541-551.
8. 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumour xenografts. Cancer 1991; 67: 1544-1550.
9. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-427.
10. Böni R, Huch Böni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluodne-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-562.
11. Steinert H, Huch Böni RA, Böni R, et al. Malignant melanoma: staging with whole-body FDG-PET [abstract]. J Nucl Med 1995; 36: 191P.
12. Pounds TR, Valk PE, Hasemann MK, et al. Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: comparison to CT [abstract]. J Nucl Med 1995; 36: 116P.
13. Steinert HC, Huch Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
14. Balch CM, Soong S, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Sober AJ, et al., eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. 2nd edition. Philadelphia: JB Lippincott, 1992: 165-187.
15. Karakousis CP, Velez A, Driscoll DL, et al. Metastasectomy in malignant melanoma. Surgery 1994; 115: 295-302.
16. Wong JH, Skinner KA, Kim KA, et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993; 113: 389-394.
17. Meikle SR, Bailey DL, Hooper PK, et al. Attenuation correction in whole-body PET using simultaneous emission transmission scanning and accelerated EM reconstruction. J Nucl Med 1995; 36: 1680-1688.
18. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th edition. Philadelphia: JB Lippincott, 1993: 1612-1661.
19. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-913.
20. Strauss LG, Dimitrakopoulou A, van Kaick G. PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior and after therapy [abstract]. J Nucl Med 1994; 35: 38P.
21. Yao WJ, Hoh CK, Glaspy JA, et al. Whole body FDG PET imaging for staging of malignant melanoma: is it cost-effective? [abstract]. J Nucl Med 1994; 35: 8P.